EPS for Shire plc (SHPG) Expected At $3.58

April 25, 2018 - By Nellie Frank

Shire plc (NASDAQ:SHPG) Logo

Analysts expect Shire plc (NASDAQ:SHPG) to report $3.58 EPS on April, 26 before the open.They anticipate $0.05 EPS change or 1.38 % from last quarter’s $3.63 EPS. SHPG’s profit would be $1.06 billion giving it 11.06 P/E if the $3.58 EPS is correct. After having $3.98 EPS previously, Shire plc’s analysts see -10.05 % EPS growth. The stock decreased 3.39% or $5.56 during the last trading session, reaching $158.37. About 4.00M shares traded or 163.62% up from the average. Shire plc (NASDAQ:SHPG) has declined 27.67% since April 26, 2017 and is downtrending. It has underperformed by 39.22% the S&P500.

Shire plc (NASDAQ:SHPG) Ratings Coverage

Among 14 analysts covering Shire (NASDAQ:SHPG), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Shire had 24 analyst reports since October 26, 2017 according to SRatingsIntel. The firm has “Outperform” rating by Bernstein given on Wednesday, February 14. Bank of America maintained Shire plc (NASDAQ:SHPG) on Wednesday, March 28 with “Buy” rating. The firm has “Buy” rating by Cowen & Co given on Friday, October 27. SunTrust maintained Shire plc (NASDAQ:SHPG) rating on Thursday, October 26. SunTrust has “Buy” rating and $260.0 target. The rating was downgraded by J.P. Morgan to “Hold” on Monday, February 19. The firm has “Hold” rating by Piper Jaffray given on Wednesday, February 14. Stifel Nicolaus maintained Shire plc (NASDAQ:SHPG) on Tuesday, January 2 with “Buy” rating. Cowen & Co maintained the stock with “Buy” rating in Friday, January 5 report. The rating was maintained by RBC Capital Markets with “Buy” on Monday, February 5. As per Wednesday, November 15, the company rating was maintained by Susquehanna.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company has market cap of $46.93 billion. The firm offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. It has a 11.28 P/E ratio. The Company’s marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease.

Shire plc (NASDAQ:SHPG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: